ArticleEmerging infectious diseases2016
Yellow Fever-More a Policy and Planning Problem than a Biological One.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05374317 (An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
Who cites it
9 citing papers in PubMed.
- A proposed One Health approach to control yellow fever outbreaks in Uganda.One health outlook · 2024Review
- A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response.PLoS pathogens · 2022Article
- Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus.Antiviral research · 2020Article
- Review
- Arbovirus-Mosquito Vector-Host Interactions and the Impact on Transmission and Disease Pathogenesis of Arboviruses.Frontiers in microbiology · 2019Review
- Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.Trends in microbiology · 2018Review
- Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production.Applied microbiology and biotechnology · 2018Article
- ProMED-mail: 22 years of digital surveillance of emerging infectious diseases.International health · 2017Review
- REPORTING DELAY DURING THE YELLOW FEVER OUTBREAK, ANGOLA, 2016.Revista do Instituto de Medicina Tropical de Sao Paulo · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.